-+ 0.00%
-+ 0.00%
-+ 0.00%

AKARI THERAPEUTICS REPORTS POSITIVE PRECLINICAL DATA FOR AKTX-101 DEMONSTRATING DIFFERENTIATED CYTOTOXICITY FOR FIRST-IN-CLASS TROP2 ADC PAYLOAD TARGETING RNA SPLICING

Reuters·04/20/2026 12:35:11

Please log in to view news